A DRB (5,6 dichloro-beta-D-ribofuranosylbenzimidazole)-resistant adenovirus mRNA.
AUTOR(ES)
Vennström, B
RESUMO
5,6-Dichloro-beta-D ribofuranosyl benzimidazole (DRB) inhibits transcription from the major late adenovirus promoter, located on the r-strand at map position 16.3 on the viral genome. 100-500 nucleotides long RNA chains with capped 5'-termini are transcribed from this promoter in the presence of 70 muM DRB. Synthesis of the mRNA for polypeptide IX which is unspliced and maps on the r-strand between positions 9.7 and 10.9 appears, however, to be DRB-resistant although it is transcribed by polymerase II and capped. Translatable mRNA for polypeptide IX is synthesized in the presence of DRB while the mRNAs for the other viral structural proteins are not synthesized. This differential DRB-inhibition of polymerase II transcription suggests either that short mRNAs may escape inhibition or that unspliced mRNAs are insensitive to the drug.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=342316Documentos Relacionados
- Induction of premature termination of transcription of the mouse beta-globin gene by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB).
- Multiple discrete sites for premature RNA chain termination late in adenovirus-2 infection: enhancement by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.
- Isolation and characterization of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole-resistant mutants of the Chinese hamster ovary cell line.
- Early termination of heterogeneous nuclear RNA transcripts in mammalian cells: accentuation by 5,6-dichloro 1-beta-D-ribofuranosylbenzimidazole.
- Serum enhances the cycling and survival of HeLa cells treated with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.
